Please try another search
National Graphite Corp., formerly Lucky Boy Silver Corporation, is a biopharmaceutical risk/cost-sharing company. The Company is pursuing the commercial development of a drug candidate, elafin, for the treatment of postoperative inflammatory complications. Elafin is a human identic protein. The Company operates in Germany, in collaboration with clinical-stage companies that develop new biological entities or new therapeutically platforms in the treatment for various diseases, rare diseases and diseases with unmet needs. Biotech Development Corp. is the Company's subsidiary. As of February 28, 2015, the Company had not generated any revenues.
Name | Age | Since | Title |
---|---|---|---|
Verena Becchio | 79 | 2015 | Secretary & Director |
Ulrike Dickmann | 68 | 2014 | Chief Executive Officer, President, Chief Financial Officer and Director |
Hansjuerg Haas | - | 2015 | Member of Advisory Board |
Rainer Feustel | - | 2015 | Member of Advisory Board |
Radulf C. Oberthuer | - | 2015 | Member of Advisory Board |
Bruno Becchio | - | 2015 | Member of Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review